CN107970219A - Pet meloxicam tablet and its preparation method and application - Google Patents
Pet meloxicam tablet and its preparation method and application Download PDFInfo
- Publication number
- CN107970219A CN107970219A CN201711451347.8A CN201711451347A CN107970219A CN 107970219 A CN107970219 A CN 107970219A CN 201711451347 A CN201711451347 A CN 201711451347A CN 107970219 A CN107970219 A CN 107970219A
- Authority
- CN
- China
- Prior art keywords
- meloxicam
- pet
- tablet
- micronizing
- basifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 title claims abstract description 214
- 229960001929 meloxicam Drugs 0.000 title claims abstract description 212
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000002245 particle Substances 0.000 claims abstract description 33
- 238000000227 grinding Methods 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 239000007884 disintegrant Substances 0.000 claims abstract description 21
- 239000000314 lubricant Substances 0.000 claims abstract description 21
- 239000003085 diluting agent Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000011230 binding agent Substances 0.000 claims abstract description 18
- -1 glidant Substances 0.000 claims abstract description 15
- 238000005469 granulation Methods 0.000 claims abstract description 8
- 230000003179 granulation Effects 0.000 claims abstract description 8
- 208000031295 Animal disease Diseases 0.000 claims abstract description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 38
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 33
- 229920002472 Starch Polymers 0.000 claims description 27
- 235000019698 starch Nutrition 0.000 claims description 27
- 239000008107 starch Substances 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 26
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 26
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 26
- 229940069328 povidone Drugs 0.000 claims description 26
- 239000001509 sodium citrate Substances 0.000 claims description 23
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 23
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 22
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 22
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 21
- 239000011734 sodium Substances 0.000 claims description 20
- 229910052708 sodium Inorganic materials 0.000 claims description 20
- 239000008101 lactose Substances 0.000 claims description 18
- 239000011265 semifinished product Substances 0.000 claims description 14
- 239000000377 silicon dioxide Substances 0.000 claims description 14
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- 229920000881 Modified starch Polymers 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 9
- 235000012241 calcium silicate Nutrition 0.000 claims description 8
- 229960000913 crospovidone Drugs 0.000 claims description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000011122 softwood Substances 0.000 claims description 7
- 235000020985 whole grains Nutrition 0.000 claims description 7
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000001540 sodium lactate Substances 0.000 claims description 6
- 229940005581 sodium lactate Drugs 0.000 claims description 6
- 235000011088 sodium lactate Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 229960001790 sodium citrate Drugs 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 229940083542 sodium Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 244000248349 Citrus limon Species 0.000 claims 2
- 235000005979 Citrus limon Nutrition 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 20
- 239000003595 mist Substances 0.000 abstract description 5
- 230000000857 drug effect Effects 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 2
- 239000012467 final product Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 62
- 239000003814 drug Substances 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000012752 auxiliary agent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000282326 Felis catus Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 235000019733 Fish meal Nutrition 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000004467 fishmeal Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000007962 solid dispersion Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000001508 potassium citrate Substances 0.000 description 4
- 229960002635 potassium citrate Drugs 0.000 description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 4
- 235000011082 potassium citrates Nutrition 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003194 meglumine Drugs 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229940001593 sodium carbonate Drugs 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- YCSMVPSDJIOXGN-UHFFFAOYSA-N CCCCCCCCCCCC[Na] Chemical compound CCCCCCCCCCCC[Na] YCSMVPSDJIOXGN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005434 MCC/mannitol excipient Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- VWDWKYIASSYTQR-YTBWXGASSA-N sodium;dioxido(oxo)azanium Chemical compound [Na+].[O-][15N+]([O-])=O VWDWKYIASSYTQR-YTBWXGASSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses pet meloxicam tablet and its preparation method and application.The pet includes following component with meloxicam tablet：Meloxicam, basifier, diluent, disintegrant, glidant, lubricant, and appropriate binder；The part by weight of the Meloxicam is 0.5% 1.25%, and the part by weight of the basifier is 5% 15%, and the Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, and the particle diameter of the micronizing Meloxicam is not more than 75 μm；The preparation method of the meloxicam tablet is that Meloxicam is carried out micro mist, and then disintegrant, diluent, basifier are mixed according to equal increments method, obtains mixture, binder is added in the mixture, and then quick granulation, obtains wet granular, glidant and lubricant are added after drying, tabletting to obtain the final product；Above-mentioned meloxicam tablet is used to prevent, treat joint of animal disease.Pet meloxicam tablet of the present invention, its dissolution rate is high, is conducive to drug effect performance.
Description
Technical field
The present invention relates to pet field of pharmaceutical technology, and in particular to pet meloxicam tablet and preparation method thereof and should
With.
Background technology
Meloxicam is a kind of non-steroid antiinflammatory of dilute alcohol amide-type, being capable of preference suppression COX-2, head
First listed in Germany, and be applied to Human clinical in France, Sweden, the granted listing of Switzerland, more of China production of units.Mei Luo
Former times health has the effect such as stronger anti-inflammatory, analgesia, antipyretic, and clinical research shows that the adverse reaction to intestines and stomach and kidney is smaller.
Multiple countries such as moral, American and Britain apply on veterinary clinic, achieve good result, the domestic application on pet at present is also
In the experimental study stage.Meloxicam is white or pale yellow crystals or crystalline solid powder, and insensitive to light, chemical property is steady
It is fixed, it is practically insoluble in water, difficult penetrating pharmaceutical.
In pharmaceutical field, since the medicine for being insoluble in water is slower in intestines and stomach rate of dissolution, it is restricted drug absorption.
Increase the solubility of insoluble drug to improve the dissolution rate of medicine, promote absorption of the medicine in body, so as to improve medicine
Clinical efficacy, it has also become the emphasis and difficult point of pharmaceutical preparation exploitation.The quality of tablet and raw material, auxiliary material, particle in pharmaceutical preparation
The factor such as size, pellet hardness and composition and process conditions is all related, and dissolution rate is as pharmaceutical preparation quality control
Important indicator is also influenced by above-mentioned factor, therefore the data of dissolution rate can directly reflect the quality of tablet.
Chinese invention patent CN103705479A, there is provided a kind of pet is with Meloxicam sustained-release tablet and its prepares work
Skill, the solid dispersions of its Meloxicam by Meloxicam and meglumine co-dissolve by aqueous solution, passing through vacuum
The solid dispersions that are dried to obtain improve dissolution rate.But its preparation method is more numerous and diverse, it is unfavorable for large-scale promotion production.
The content of the invention
Based on this, the present invention provides a kind of drug dissolution high pet meloxicam tablet.
The present invention also provides the preparation method of above-mentioned pet meloxicam tablet, its method is simple, beneficial to popularization.
The present invention also provides the application of above-mentioned pet meloxicam tablet.
In order to achieve the object of the present invention, the present invention uses following technical scheme：
A kind of pet meloxicam tablet, it includes following component：
Meloxicam, basifier, diluent, disintegrant, glidant, lubricant, and appropriate binder；The Meloxicam
Part by weight be 0.5%-1.25%, the part by weight of the basifier is 5%-15%, and the Meloxicam is Ultramicro-powder
Broken to prepare the micronizing Meloxicam formed, the particle diameter of the micronizing Meloxicam is not more than 75 μm.
Above-mentioned pet meloxicam tablet, using the Meloxicam of micronizing, forms with reference to basifier and other auxiliary agents
Meloxicam Tablets, the Meloxicam particle diameter very little of micronizing, more contribute to be rapidly dissolved in body, and basifier for
The Meloxicam of micronizing can play local micro- alkali effect, and dissolution assistant effect is played to Meloxicam, relative to the prior art, its
Dissolution rate higher, dissolves faster, so as to help quickly to play drug effect.
In some of embodiments, the pet meloxicam tablet, further includes flavouring.Flavouring can increase medicine
The palatability of thing, is more favorable for being administered.
In some of embodiments, the particle diameter of the micronizing Meloxicam is 30 μm -75 μm.
In some of embodiments, the basifier is one kind in sodium citrate, potassium citrate, sodium carbonate and sodium lactate
It is or several.
In some of embodiments, the diluent is lactose, microcrystalline cellulose, mannitol, pregelatinized starch and micro mist
One or more in silica gel microcrystalline cellulose.
In some of embodiments, the disintegrant is sodium carboxymethyl starch, crospovidone, low-substituted hydroxypropyl first fiber
One or more in element and pregelatinized starch.Using disintegrant medicine can be made to disintegrate tablet configuration after contact with water and be allowed to
It is broken, surface area of the increase medicine in dissolution medium, beneficial to drug-eluting.
In some of embodiments, the glidant is one kind in calcium silicates, cataloid, starch and talcum powder
It is or several.
In some of embodiments, the meloxicam tablet includes following component：It is Meloxicam, sodium citrate, lactose, micro-
Crystalline cellulose, sodium carboxymethyl starch, silica, lauryl sodium sulfate, and 5% povidone aqueous solution are appropriate；U.S. Lip river
The part by weight of former times health is 0.5%-1.25%, and the part by weight of the sodium citrate is 5%-15%, and the Meloxicam is
Ultramicro grinding prepares the micronizing Meloxicam to be formed, and the particle diameter of the micronizing Meloxicam is not more than 75 μm.
The present invention, which there is a need to, provides a kind of preparation method of pet meloxicam tablet, it includes the following steps：
Meloxicam, basifier, diluent, disintegrant, glidant, lubricant, and appropriate binder are provided；U.S. Lip river
The part by weight of former times health is 0.5%-1.25%, and the part by weight of the basifier is 5%-15%；
The Meloxicam is placed in Ultra-Micro Grinding Equipment and is micronized, obtains the micro mist that particle diameter is not more than 75um
Change Meloxicam；
The micronizing Meloxicam is mixed with disintegrant, diluent, basifier according to equal increments method, must be mixed
Thing；
Binder is added in the mixture, is uniformly mixed, softwood is made, then quick granulation, obtains wet granular；
The wet granular is dried at 50 DEG C -60 DEG C to moisture in 2%-3.5%, then whole grain, obtains semi-finished product；
Glidant and lubricant are added in the semi-finished product, is uniformly mixed, tabletting, obtains the meloxicam tablet.
The preparation method of above-mentioned pet meloxicam tablet, its technique is simple, can equably mix main ingredient and auxiliary agent
It is combined so that auxiliary agent can preferably play a role, and improve the dissolution rate of medicine, and be adapted to industrialization to produce, and have wide
Wealthy application prospect.
In addition, the present invention, which there is a need to, provides a kind of pet with meloxicam tablet for preventing, treating joint of animal disease
Application.
Embodiment
For the ease of understanding the present invention, the present invention will be described more fully below.But the present invention can be with perhaps
More different form is realized, however it is not limited to embodiment described herein.On the contrary, the purpose for providing these embodiments is to make
Understanding more thorough and comprehensive to the disclosure.
Unless otherwise defined, all of technologies and scientific terms used here by the article is with belonging to technical field of the invention
The normally understood implication of technical staff is identical.Term used in the description of the invention herein is intended merely to description tool
The purpose of the embodiment of body, it is not intended that in the limitation present invention.
The test method of actual conditions is not specified in the following example, according to conventional methods and conditions, or says according to commodity
The adjusting of bright book suggestion makes choice.Reagents or instruments used without specified manufacturer, is that can be obtained by commercially available purchase
Conventional products.
Pet meloxicam tablet of the present invention, for preventing and treating joint relevant disease.
The pet meloxicam tablet, is the tablet using Meloxicam as the resistance joint disease of main component, its
Including following component：Meloxicam, basifier, diluent, disintegrant, glidant, lubricant, and appropriate binder；It is described
The part by weight of Meloxicam is 0.5%-1.25%, and the part by weight of the basifier is 5%-15%, the Meloxicam
The micronizing Meloxicam to be formed is prepared for ultramicro grinding, the particle diameter of the micronizing Meloxicam is not more than 75 μm.
Specifically：Meloxicam 0.5%-1.25%, basifier 5%-15%, diluent 50%-85%, disintegrant
2%-15%, glidant 0.05%-10%, lubricant 0.05%-10%, and appropriate binder；Its Meloxicam is ultra micro
The micronizing Meloxicam for preparing and being formed is crushed, the particle diameter for being micronized Meloxicam is not more than 75 μm.
In a wherein embodiment, the volume of binder can be 20-30 times of the quality of Meloxicam.
Meloxicam 0.5%-1.25%, such as can be, but be not limited to 0.5%, 0.7%, 0.8%, 1%, 1.1%,
1.2%th, 1.25% etc., it is preferably 0.83%；Basifier 5%-15%, such as can be, but be not limited to 5%, 6%, 7%,
8%th, 10%, 12%, 15% etc.；Diluent 50%-85%, such as can be, but be not limited to 50%, 55%, 60%, 65%,
70%th, 75%, 80%, 85% etc.；Disintegrant 2%-15%, such as can be, but be not limited to 2%, 3%, 5%, 8%, 9%,
10%th, 12%, 15% etc.；Glidant 0.05%-10%, such as can be, but be not limited to 0.05%, 0.1%, 0.5%, 1%,
2%th, 4%, 7%, 8%, 10% etc.；Lubricant 0.05%-10%, such as can be, but be not limited to 0.05%, 0.1%,
0.5%th, 1%, 2%, 4%, 7%, 8%, 10% etc., appropriate binder, total weight percent is maintained at 100%.
Further, the particle diameter of Meloxicam is micronized at 30 μm -75 μm.Further, it is preferable to it is 75 μm, which makes
Meloxicam is obtained to be easier to be combined together with other auxiliary agents.
Further, above-mentioned pet meloxicam tablet, further includes flavouring, may be selected in part by weight 5%-20%.
Flavouring can increase the palatability of medicine, be more favorable for being administered.Flavouring 5%-20%, such as can be, but be not limited to
5%th, 6%, 7%, 8%, 10%, 12%, 15%, 18%, 20% etc..Flavouring includes powdered beef, chicken liver meal, fish meal etc., can
To be added according to the requirement of pet, such as cat can add fish meal with Meloxicam, doggie use can add powdered beef or
Chicken liver meal.
In a wherein embodiment, basifier is one kind or several in sodium citrate, potassium citrate, sodium carbonate and sodium lactate
Kind.Basifier plays the role of playing local micro- alkali, and dissolution assistant effect is played to main ingredient Meloxicam.Such as sodium citrate can be selected
With potassium citrate with 1：1 compounding is added as basifier together.Can also individually select sodium lactate as basifier into
Row addition.Alternatively, selection sodium carbonate and sodium lactate are with 1:2 compoundings are added as basifier together.
In a wherein embodiment, diluent is lactose, microcrystalline cellulose, mannitol, pregelatinized starch and superfine silica gel powder are micro-
One or more in crystalline cellulose.Diluent can increase piece weight, lift compressibility, can be in favor of being fabricated to tablet.Such as
Diluent can select lactose or microcrystalline cellulose；It is also an option that microcrystalline cellulose and mannitol are with 1:1 compounding is made together
It is added for diluent；It is also an option that pregelatinized starch and superfine silica gel powder microcrystalline cellulose are with 2:1 ratio is compounded one
Rise and be added as diluent.
In a wherein embodiment, disintegrant is sodium carboxymethyl starch, crospovidone, low-substituted hydroxypropyl methylcellulose and pre-
One or more in gelling starch.Using disintegrant medicine can be made to disintegrate tablet configuration after contact with water and be allowed to broken,
Increase surface area of the medicine in dissolution medium, beneficial to drug-eluting.Disintegrant for example can be sodium carboxymethyl starch；Or hand over
Join povidone；It is also an option that by crospovidone and low-substituted hydroxypropyl methylcellulose with 1:1 ratio compounding conduct together
Disintegrant is added；It is also an option that pregelatinized starch is added as disintegrant.
In a wherein embodiment, glidant is one kind or several in calcium silicates, cataloid, starch and talcum powder
Kind.Glidant can improve interparticle mobility, accelerate the speed being mutually dissolved, so as to be beneficial to tablet is made.Glidant example
Such as can be calcium silicates or cataloid；It is also an option that calcium silicates and cataloid are with 1:1 ratio compounding shape
Into；It is also an option that starch or talcum powder.
In a wherein embodiment, lubricant be magnesium stearate, lauryl sodium sulfate, talcum powder and starch in one kind or
It is several.Lubricant is overcoming the frictional force between tablet and punch die.Lubricant for example can be magnesium stearate or dodecyl
Sodium sulphate or talcum powder and starch 1:1 compounding forms.
In a wherein embodiment, flavouring is the one or more in powdered beef, chicken liver meal and fish meal.Flavouring is increasing
The palatability of dosing thing.Flavouring can make choice according to the pet taste of medication.
In some of embodiments, the pet meloxicam tablet, is the resistance using Meloxicam as main component
The tablet of joint disease, it includes following component：Meloxicam, sodium citrate, lactose, microcrystalline cellulose, sodium carboxymethyl starch,
Silica, lauryl sodium sulfate, and 5% povidone aqueous solution are appropriate；The part by weight of the Meloxicam is 0.5%-
1.25%, the part by weight of the sodium citrate is 5%-15%, and the Meloxicam prepares the micro mist to be formed for ultramicro grinding
Change Meloxicam, the particle diameter of the micronizing Meloxicam is not more than 75 μm.
Specifically：Meloxicam 0.5%-1.25%, sodium citrate 5%-15%, lactose 25%-39%, microcrystalline cellulose
Plain 25%-41%, sodium carboxymethyl starch 2%-15%, silica 0.05%-10%, lauryl sodium sulfate 0.05%-
10%, and 5% povidone aqueous solution is appropriate；The Meloxicam prepares the micronizing Meloxicam to be formed, institute for ultramicro grinding
The particle diameter for stating micronizing Meloxicam is not more than 75 μm.
In a wherein embodiment, the volume of binder can be 20-30 times of the quality of Meloxicam.
Meloxicam 0.5%-1.25%, such as can be, but be not limited to 0.5%, 0.7%, 0.8%, 1%, 1.1%,
1.2%th, 1.25% etc.；Sodium citrate 5%-15%, such as can be, but be not limited to 5%, 6%, 7%, 8%, 10%, 12%,
15% etc.；Lactose 50%-85%, such as can be, but be not limited to 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85% etc.；5% povidone aqueous solution 2%-15%, such as can be, but be not limited to 2%, 3%, 5%, 8%, 9%, 10%,
12%th, 15% etc.；Silica 0.05%-10%, such as can be, but be not limited to 0.05%, 0.1%, 0.5%, 1%,
2%th, 4%, 7%, 8%, 10% etc.；Lauryl sodium sulfate 0.05%-10%, such as can be, but be not limited to 0.05%,
0.1%th, 0.5%, 1%, 2%, 4%, 7%, 8%, 10% etc., appropriate microcrystalline cellulose, total weight percent is maintained at
100%.
The pet meloxicam tablet, its dissolution rate is higher relative to other compositions after preparation forms tablet, be it is a kind of compared with
Excellent formula.
Above-mentioned pet meloxicam tablet, using the Meloxicam of micronizing, forms with reference to basifier and other auxiliary agents
Meloxicam Tablets, the Meloxicam particle diameter very little of micronizing, more contribute to be rapidly dissolved in body, and basifier for
The Meloxicam of micronizing can play local micro- alkali effect, and dissolution assistant effect is played to Meloxicam, relative to the prior art, its
Dissolution rate higher, dissolves faster, so as to help quickly to play drug effect.
The present invention also provides the preparation method of above-mentioned pet meloxicam tablet, it includes the following steps：
First, Meloxicam is placed in Ultra-Micro Grinding Equipment and is micronized, obtain the micronizing that particle diameter is not more than 75um
Meloxicam, wherein preferably particle diameter, in 30um-75um, optimal is 75um.Particle diameter can be selected in Ultra-Micro Grinding Equipment, also
It can sieve and make choice after micro mist.
Two then by micronizing Meloxicam mixed with disintegrant, diluent, basifier according to equal increments method, obtain mixed
Compound；The big component of the amount of a small amount of components and equivalent is taken, while is placed in mixing machinery and is uniformly mixed, is added with mixing
The component that the amount of thing equivalent is big is uniformly mixed, and so a times amount is increased up untill adding the big component of whole amount.Above-mentioned U.S. Lip river former times
After health determines proportioning with disintegrant, diluent, basifier, mixed according to above-mentioned method.
3rd, binder is added in the mixture, is uniformly mixed, softwood is made, and then quick granulation, obtains wet granular；
The 4th, wet granular is dried to moisture at 50 DEG C -60 DEG C in 2%-3.5%, then whole grain, obtains semi-finished product；
5th, glidant and lubricant are added in semi-finished product, is uniformly mixed, tabletting, obtains meloxicam tablet.
Above-mentioned meloxicam tablet, preferably piece weight are 0.2g-0.5g, are more suitable for the administration of small-sized cat, dog etc..
The preparation method of above-mentioned pet meloxicam tablet, its technique is simple, can equably mix main and auxiliary agent
It is combined so that auxiliary agent can preferably play a role, and improve the dissolution rate of medicine, and be adapted to industrialization to produce, and have wide
Wealthy application prospect.
In addition, be used to meloxicam tablet preventing, treating the application of joint of animal disease the present invention also provides a kind of pet,
Animal is administered using the meloxicam tablet, because its dissolution rate is higher, the treatment progress of the state of an illness can be accelerated.
The implementation of the present invention will be further illustrated by several embodiments below.
Embodiment one
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
0.86%th, sodium citrate 8.6%, lactose 37.8%, microcrystalline cellulose 40%, sodium carboxymethyl starch 8%, silica 0.2%,
Lauryl sodium sulfate 1%, powdered beef 3.54%, and 5% povidone aqueous solution, the volume of 5% povidone aqueous solution is U.S. Lip river
23.2 times of the quality of former times health；Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, is micronized Meloxicam
Particle diameter be 75 μm.
Above-mentioned pet meloxicam tablet, its preparation method are：Meloxicam is placed in Ultra-Micro Grinding Equipment and is carried out
Micronizing, obtains the micronizing Meloxicam that particle diameter is 75um；Then will micronizing Meloxicam and sodium carboxymethyl starch, breast
Sugar, microcrystalline cellulose and sodium citrate are mixed according to equal increments method, obtain mixture, that is, the amount for measuring small component and equivalent is big
Component, while be placed in mixing machinery and be uniformly mixed, the big component of amount for adding same mixture equivalent is uniformly mixed, so times
Amount is increased up untill adding the big component of whole amount；Binder is added in the mixture, is uniformly mixed, and softwood is made, then
Quick granulation, obtains wet granular；Wet granular is dried at 55 DEG C to moisture 2.5%, then whole grain, obtains semi-finished product；In semi-finished product
Middle addition glidant and lubricant, are uniformly mixed, tabletting, obtains meloxicam tablet.
Above-mentioned meloxicam tablet, piece weight are 0.3g, are more suitable for the administration of small-sized cat, dog etc..
Embodiment two
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
0.5%th, sodium citrate 15%, lactose 39%, microcrystalline cellulose 41%, sodium carboxymethyl starch 2%, silica 1 .5%, 12
Sodium alkyl sulfate 1%, and 5% povidone aqueous solution, the volume of 5% povidone aqueous solution are 20 times of the quality of Meloxicam；
Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, and the particle diameter for being micronized Meloxicam is 45 μm.
Above-mentioned pet meloxicam tablet, its preparation method are：Meloxicam is placed in Ultra-Micro Grinding Equipment and is carried out
Micronizing, obtains the micronizing Meloxicam that particle diameter is 45um；Then will micronizing Meloxicam and sodium carboxymethyl starch, breast
Sugar, microcrystalline cellulose and sodium citrate are mixed according to equal increments method, obtain mixture, that is, the amount for measuring small component and equivalent is big
Component, while be placed in mixing machinery and be uniformly mixed, the big component of amount for adding same mixture equivalent is uniformly mixed, so times
Amount is increased up untill adding the big component of whole amount；Binder is added in the mixture, is uniformly mixed, and softwood is made, then
Quick granulation, obtains wet granular；Wet granular is dried at 50 DEG C to moisture 2%, then whole grain, obtains semi-finished product；In semi-finished product
Glidant and lubricant are added, is uniformly mixed, tabletting, obtains meloxicam tablet.
Above-mentioned meloxicam tablet, piece weight are 0.3g, are more suitable for the administration of small-sized cat, dog etc..
Embodiment three
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
1.25%th, sodium citrate 5%, lactose 33.75%, microcrystalline cellulose 25%, sodium carboxymethyl starch 15%, silica 1 0%,
Lauryl sodium sulfate 10%, and 5% povidone aqueous solution, the volume of 5% povidone aqueous solution is the quality of Meloxicam
20 times；Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, and the particle diameter for being micronized Meloxicam is 30 μm.
Above-mentioned pet meloxicam tablet, its preparation method are：Meloxicam is placed in Ultra-Micro Grinding Equipment and is carried out
Micronizing, obtains the micronizing Meloxicam that particle diameter is 30um；Then will micronizing Meloxicam and sodium carboxymethyl starch, breast
Sugar, microcrystalline cellulose and sodium citrate are mixed according to equal increments method, obtain mixture, that is, the amount for measuring small component and equivalent is big
Component, while be placed in mixing machinery and be uniformly mixed, the big component of amount for adding same mixture equivalent is uniformly mixed, so times
Amount is increased up untill adding the big component of whole amount；Binder is added in the mixture, is uniformly mixed, and softwood is made, then
Quick granulation, obtains wet granular；Wet granular is dried at 60 DEG C to moisture 2%, then whole grain, obtains semi-finished product；In semi-finished product
Glidant and lubricant are added, is uniformly mixed, tabletting, obtains meloxicam tablet.
Above-mentioned meloxicam tablet, piece weight are 0.4g, are more suitable for the administration of small-sized cat, dog etc..
Example IV
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
1.25%th, sodium citrate 15%, lactose 25%, microcrystalline cellulose 40%, sodium carboxymethyl starch 15%, silica 0.05%,
Lauryl sodium sulfate 0.05%, fish meal 3.65%, and 5% povidone aqueous solution, the volume of 5% povidone aqueous solution is U.S. Lip river
30 times of the quality of former times health；Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, is micronized Meloxicam
Particle diameter is 30 μm.
Above-mentioned pet meloxicam tablet, its preparation method are：Meloxicam is placed in Ultra-Micro Grinding Equipment and is carried out
Micronizing, obtains the micronizing Meloxicam that particle diameter is 30um；Then will micronizing Meloxicam and sodium carboxymethyl starch, breast
Sugar, microcrystalline cellulose and sodium citrate are mixed according to equal increments method, obtain mixture, that is, the amount for measuring small component and equivalent is big
Component, while be placed in mixing machinery and be uniformly mixed, the big component of amount for adding same mixture equivalent is uniformly mixed, so times
Amount is increased up untill adding the big component of whole amount；Binder is added in the mixture, is uniformly mixed, and softwood is made, then
Quick granulation, obtains wet granular；Wet granular is dried at 55 DEG C to moisture 3.5%, then whole grain, obtains semi-finished product；In semi-finished product
Middle addition glidant and lubricant, are uniformly mixed, tabletting, obtains meloxicam tablet.
Above-mentioned meloxicam tablet, piece weight are 0.5g, are more suitable for the dosage of small-sized cat, dog etc..
Embodiment five
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
1.25%th, sodium carbonate 15%, mannitol 65%, crospovidone 15%, calcium silicates 0.05%, lauryl sodium sulfate
0.05%th, fish meal 3.65%, and 5% povidone aqueous solution, the volume of 5% povidone aqueous solution is the 28 of the quality of Meloxicam
Times；Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, and the particle diameter for being micronized Meloxicam is 30 μm.
Preparation method is with dosage with embodiment one.
Embodiment six
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
0.5%th, potassium citrate 7.5%, sodium citrate 7.5%, pregelatinized starch 39%, lactose 41%, low-substituted hydroxypropyl methylcellulose
1%th, crospovidone 1%, calcium silicates 1.5%, magnesium stearate 1%, and 5% povidone aqueous solution, 5% povidone aqueous solution
Volume is 22 times of the quality of Meloxicam；Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, is micronized
The particle diameter of Meloxicam is 45 μm.
Preparation method is with dosage with embodiment two.
Embodiment seven
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
1.25%th, sodium lactate 5%, mannitol 33.75%, microcrystalline cellulose 25%, sodium carboxymethyl starch 7.5%, pregelatinized starch
7.5%th, calcium silicates 10%, magnesium stearate 10%, and 5% povidone aqueous solution, the volume of 5% povidone aqueous solution is U.S. Lip river former times
20 times of the quality of health；Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, is micronized the grain of Meloxicam
Footpath is 30 μm.
Preparation method is with dosage with embodiment three.
Embodiment eight
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
1.25%th, sodium citrate 15%, lactose 65%, crospovidone 15%, silica 0.05%, lauryl sodium sulfate
0.05%th, chicken liver meal 3.65%, and 5% povidone aqueous solution, the volume of 5% povidone aqueous solution is the quality of Meloxicam
30 times；Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, and the particle diameter for being micronized Meloxicam is 30 μm.
Preparation method and the same example IV of dosage.
Comparative example one
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
0.86%th, lactose 37.8%, microcrystalline cellulose 40%, sodium carboxymethyl starch 8%, silica 0.2%, lauryl sodium sulfate
1%th, powdered beef 3.54%, and 5% povidone aqueous solution, the volume of 5% povidone aqueous solution is the quality of Meloxicam
23.2 times；Meloxicam prepares the micronizing Meloxicam to be formed for ultramicro grinding, and the particle diameter for being micronized Meloxicam is 75 μm.
Preparation method is the same as embodiment one.
Comparative example two
Pet meloxicam tablet described in the embodiment of the present invention, is made of the component of following parts by weight：Meloxicam
1.25%th, sodium citrate 5%, lactose 33.75%, microcrystalline cellulose 25%, sodium carboxymethyl starch 15%, silica 1 0%,
Lauryl sodium sulfate 10%, and 5% povidone aqueous solution, the volume of 5% povidone aqueous solution is the quality of Meloxicam
20 times；For Meloxicam raw material without micronization processes, particle diameter is more than 90 μm.
Preparation method is the same as embodiment three.
Comparative example three
A kind of pet Meloxicam sustained release tablets, comprising：Meloxicam solid dispersions, delay controlled-release material, filler, glue
Mixture, lubricant, flavouring；The Meloxicam solid dispersions be by by Meloxicam and meglumine co-dissolve in water
In solution, by being dried in vacuo obtained solid dispersions, the molar ratio of Meloxicam and meglumine is 8:10；U.S. Lip river former times
The content of health is 1mg or 3mg/ pieces；The slow controlled-release material is sodium alginate, in hydroxypropyl methyl cellulose, carbomer
One or more kinds of combinations, dosage is 20-25% (W/W)；The filler is starch and lactose；Adhesive is poly- dimension
Ketone, water, absolute ethyl alcohol；Lubricant is talcum powder, one or more kinds of combinations in superfine silica gel powder, magnesium stearate；Flavouring
For the one or more in the liver or muscle powder, fruity perfume, vanilla flavor of the drying of the animals such as ox, sheep, pig, fowl
Combination.
The drug dissolution of embodiment one to embodiment eight and comparative example is detected below, the results are shown in Table one.
Dissolution determination method：Obtain favour thing meloxicam tablet 6, according to dissolution method (Chinese Pharmacopoeia version in 2015
Two 0,931 second methods of annex), with phosphate buffer (potassium dihydrogen phosphate 6.81g is taken, adds water 800ml to dissolve, uses 0.5mol/L
Sodium hydroxide adjusts pH to 7.5, is dissolved in water into 1000ml) 500ml be dissolution medium, rotating speed is 50 turns per minute, is grasped in accordance with the law
Make.Sample through 5,10,15,30,45min, measured according to content assaying method, calculate every dissolution rate, be averaged.
Content assaying method：This product 20 is taken, accurately weighed, finely ground, precision weighs (is approximately equivalent to Meloxicam in right amount
12.5mg), put in tool plug measuring bottle, precision plus basic methanol solution 50ml, ultrasound 10 minutes, dissolves Meloxicam, let cool, shake
It is even, 4000 turns per minute, centrifuge 5 minutes, filtration, as test solution, precision measures 20ul injection liquid chromatographs, record
Chromatogram.Separately take Meloxicam reference substance appropriate, it is accurately weighed, add basic methanol solution to dissolve and dilute and be made in every 1, ml about
Solution containing 250ug, is measured in the same method, by external standard method with calculated by peak area, to obtain the final product.
Chromatographic condition is tested with system availability：Octadecylsilane chemically bonded silica is filler (Agilent ZORBAX
SB-C18,5um, 4.6 × 250mm or the suitable chromatographic column of efficiency)：With 0.2% ammonium dibasic phosphate solution, (phosphorus acid for adjusting pH is extremely
7.0)-methanol-isopropanol (640:320:40) bit flow；Detection wavelength is 270nm, and 30 DEG C of number of theoretical plates of column temperature press U.S. Lip river
Former times Kang Feng, which is calculated, is not less than 1500.
Table one
The meloxicam tablet of the present invention it can be seen from table one, using the Meloxicam of micronizing, with reference to basifier
Meloxicam Tablets are formed with other auxiliary agents, relative to the prior art, its dissolution rate higher, dissolves faster, so as to contribute to more
Drug effect is played soon.
Embodiment described above only expresses the several embodiments of the present invention, its description is more specific and detailed, but simultaneously
Therefore the limitation to the scope of the claims of the present invention cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to the guarantor of the present invention
Protect scope.Therefore, the protection domain of patent of the present invention should be determined by the appended claims.
Claims (10)
1. a kind of pet meloxicam tablet, it is characterised in that including following component：
Meloxicam, basifier, diluent, disintegrant, glidant, lubricant, and appropriate binder；The weight of the Meloxicam
Amount ratio is 0.5%-1.25%, and the part by weight of the basifier is 5%-15%, and the Meloxicam is ultramicro grinding system
The standby micronizing Meloxicam formed, the particle diameter of the micronizing Meloxicam are not more than 75 μm.
2. pet meloxicam tablet according to claim 1, it is characterised in that further include flavouring.
3. pet meloxicam tablet according to claim 1, it is characterised in that the particle diameter of the micronizing Meloxicam
For 30 μm -75 μm.
4. pet meloxicam tablet according to claim 1, it is characterised in that the basifier is sodium citrate, lemon
One or more in lemon acid potassium, sodium carbonate and sodium lactate.
5. pet meloxicam tablet according to claim 1, it is characterised in that the diluent is lactose, crystallite is fine
Tie up the one or more in element, mannitol, pregelatinized starch and superfine silica gel powder microcrystalline cellulose.
6. pet meloxicam tablet according to claim 1, it is characterised in that the disintegrant is carboxymethyl starch
One or more in sodium, crospovidone, low-substituted hydroxypropyl methylcellulose and pregelatinized starch.
7. pet meloxicam tablet according to claim 1, it is characterised in that the glidant is calcium silicates, colloid
One or more in silica, starch and talcum powder.
8. according to claim 1-7 any one of them pet meloxicam tablets, it is characterised in that the meloxicam tablet bag
Include following component：
Meloxicam, sodium citrate, lactose, microcrystalline cellulose, sodium carboxymethyl starch, silica, lauryl sodium sulfate, and
5% povidone aqueous solution is appropriate；The part by weight of the Meloxicam is 0.5%-1.25%, the weight ratio of the sodium citrate
Example is 5%-15%, and the Meloxicam prepares the micronizing Meloxicam to be formed, micronizing U.S.'s Lip river former times for ultramicro grinding
The particle diameter of health is not more than 75 μm.
9. a kind of preparation method of pet meloxicam tablet, it is characterised in that include the following steps：
Meloxicam, basifier, diluent, disintegrant, glidant, lubricant, and appropriate binder are provided；The Meloxicam
Part by weight be 0.5%-1.25%, the part by weight of the basifier is 5%-15%；
The Meloxicam is placed in Ultra-Micro Grinding Equipment and is micronized, it is beautiful to obtain micronizing of the particle diameter no more than 75um
Luo Xikang；
The micronizing Meloxicam is mixed with disintegrant, diluent, basifier according to equal increments method, obtains mixture；
Binder is added in the mixture, is uniformly mixed, softwood is made, then quick granulation, obtains wet granular；
The wet granular is dried at 50 DEG C -60 DEG C to moisture in 2%-3.5%, then whole grain, obtains semi-finished product；
Glidant and lubricant are added in the semi-finished product, is uniformly mixed, tabletting, obtains the meloxicam tablet.
10. a kind of such as claim 1-8 any one of them pet meloxicam tablet is used to prevent, treats joint of animal disease
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711451347.8A CN107970219A (en) | 2017-12-27 | 2017-12-27 | Pet meloxicam tablet and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711451347.8A CN107970219A (en) | 2017-12-27 | 2017-12-27 | Pet meloxicam tablet and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107970219A true CN107970219A (en) | 2018-05-01 |
Family
ID=62007899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711451347.8A Withdrawn CN107970219A (en) | 2017-12-27 | 2017-12-27 | Pet meloxicam tablet and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107970219A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524523A (en) * | 2018-07-02 | 2018-09-14 | 佛山市南海东方澳龙制药有限公司 | The application of the composition of Meloxicam and Thymol, animal antipyretic-antalgic anti-inflammatory agent and preparation method thereof |
| WO2022097024A1 (en) * | 2020-11-06 | 2022-05-12 | Mylan Laboratories Ltd | Pharmaceutical composition comprising meloxicam |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546033A (en) * | 2003-12-09 | 2004-11-17 | 成都圣诺科技发展有限公司 | Orally disintegrating tablet of meloxicam and its preparation |
| WO2006041843A3 (en) * | 2004-10-04 | 2006-08-24 | Reddys Lab Ltd Dr | Pharmaceutical dosage form comprising meloxicam |
| CN101374503A (en) * | 2006-01-26 | 2009-02-25 | 东亚药品株式会社 | Quickly disintegrating tablet produced by direct dry-tabletting |
| US7572641B2 (en) * | 2005-11-22 | 2009-08-11 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions comprising meloxicam and methods of their preparation |
| CN102525974A (en) * | 2011-08-31 | 2012-07-04 | 南京仕必得生物技术有限公司 | Meloxicam tablets for dogs and cats and preparation method for meloxicam tablets |
| CN102869343A (en) * | 2010-05-05 | 2013-01-09 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Novel low concentration meloxicam tablets |
| CN103054872A (en) * | 2013-01-24 | 2013-04-24 | 宁夏康亚药业有限公司 | Meloxicam pharmaceutical composition and preparation method thereof |
| CN103705479A (en) * | 2012-09-29 | 2014-04-09 | 瑞普（天津）生物药业有限公司 | Meloxicam sustained release tablet used for pet and preparation method thereof |
| CN106619547A (en) * | 2016-11-18 | 2017-05-10 | 江苏飞马药业有限公司 | Low-specification meloxicam tablet composition and preparation method thereof |
-
2017
- 2017-12-27 CN CN201711451347.8A patent/CN107970219A/en not_active Withdrawn
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546033A (en) * | 2003-12-09 | 2004-11-17 | 成都圣诺科技发展有限公司 | Orally disintegrating tablet of meloxicam and its preparation |
| WO2006041843A3 (en) * | 2004-10-04 | 2006-08-24 | Reddys Lab Ltd Dr | Pharmaceutical dosage form comprising meloxicam |
| US7572641B2 (en) * | 2005-11-22 | 2009-08-11 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions comprising meloxicam and methods of their preparation |
| CN101374503A (en) * | 2006-01-26 | 2009-02-25 | 东亚药品株式会社 | Quickly disintegrating tablet produced by direct dry-tabletting |
| CN102869343A (en) * | 2010-05-05 | 2013-01-09 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Novel low concentration meloxicam tablets |
| CN102525974A (en) * | 2011-08-31 | 2012-07-04 | 南京仕必得生物技术有限公司 | Meloxicam tablets for dogs and cats and preparation method for meloxicam tablets |
| CN103705479A (en) * | 2012-09-29 | 2014-04-09 | 瑞普（天津）生物药业有限公司 | Meloxicam sustained release tablet used for pet and preparation method thereof |
| CN103054872A (en) * | 2013-01-24 | 2013-04-24 | 宁夏康亚药业有限公司 | Meloxicam pharmaceutical composition and preparation method thereof |
| CN106619547A (en) * | 2016-11-18 | 2017-05-10 | 江苏飞马药业有限公司 | Low-specification meloxicam tablet composition and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张强，等: "《药剂学》", 30 September 2011, 上海科学技术出版社 * |
| 陈长洲: "《微米中药 中药超细粉体的研究及应用》", 31 August 2007, 北京：中国医药科技出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524523A (en) * | 2018-07-02 | 2018-09-14 | 佛山市南海东方澳龙制药有限公司 | The application of the composition of Meloxicam and Thymol, animal antipyretic-antalgic anti-inflammatory agent and preparation method thereof |
| WO2022097024A1 (en) * | 2020-11-06 | 2022-05-12 | Mylan Laboratories Ltd | Pharmaceutical composition comprising meloxicam |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3563036B2 (en) | Celecoxib composition | |
| JP5875231B2 (en) | Pharmaceutical composition comprising pimobendan | |
| BR112020024107A2 (en) | pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and sglt-2 inhibitor and methods of preparing and using them | |
| US20120015984A1 (en) | Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients | |
| JP2009524658A (en) | Levetiracetam preparation and method for producing the same | |
| TW202112376A (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| US20230190732A1 (en) | Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor | |
| CA3019508A1 (en) | Oral preparation having exceptional elutability | |
| CN105250231A (en) | Drug combination containing etoricoxib and preparation method thereof | |
| CN105343030A (en) | Celecoxib capsule and preparation method thereof | |
| CN106265581B (en) | Tranexamic acid tablet and preparation method thereof | |
| CN104814931B (en) | A kind of olaquindox slow-releasing granules and its preparation method and application | |
| CN105935358A (en) | Sacubitril / valsartan sustained release agent and preparation method thereof | |
| CN107970219A (en) | Pet meloxicam tablet and its preparation method and application | |
| CN107595871A (en) | Compound preparation containing ivermectin and preparation method thereof | |
| JP2022544167A (en) | Pharmaceutical composition containing nitroxoline, nitroxoline oral solid tablet, method of preparation thereof, and use thereof | |
| CN108261401B (en) | Ivermectin solid dispersion and ivermectin tablet | |
| JP4756153B2 (en) | Method for producing tablets with low content | |
| CN108524523A (en) | The application of the composition of Meloxicam and Thymol, animal antipyretic-antalgic anti-inflammatory agent and preparation method thereof | |
| CN107744509B (en) | Mosapride citrate tablet and preparation method thereof | |
| CN104473922B (en) | Composite tablet and preparation method thereof | |
| CN104188951B (en) | A kind of diacetyl rhein compositions and preparation method thereof | |
| CN113768889B (en) | Cilostazol-containing pharmaceutical composition and preparation method thereof | |
| JP2002503707A (en) | Spray-dried powders having a high edible oil content based on non-hydrolysed gelatin and a process for producing such spray-dried powders which can be made into tablets | |
| JPH04368330A (en) | Extended release formulation of pemirolast potassium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180501 |
|
| WW01 | Invention patent application withdrawn after publication |